Luma Group

Luma Group is a San Francisco-based venture firm investing in healthcare companies, with a focus on biotech and pharma and therapeutics. The firm backs companies advancing scientifically rigorous programs through clinical development and supports them as they scale toward registrational milestones and commercial readiness. Its base in San Francisco places it close to leading academic medical centers, biotech ecosystems, and venture and crossover capital sources active in the sector. Specific portfolio company names and partner-level detail are not provided in the input, so this profile reflects the firm’s stated focus and structural characteristics rather than individual investments.

Luma writes checks of $5M to $25M and invests at Series A and Series B stages. Headquartered in the United States, the firm typically engages with companies that have validated their core science and are entering or advancing through clinical development. The stage range allows it to support companies through key inflection points, often alongside specialist biotech syndicates and crossover investors.

For founders and management teams, Luma is most relevant when a biotech or pharma program has clear scientific differentiation and a credible plan to advance through Series A and Series B development milestones. The firm prefers teams that engage directly on data, clinical strategy, and capital planning across the long arcs typical of drug development. Founders should expect rigorous scientific diligence, a partner experienced with biotech syndicate dynamics, and engagement on clinical execution, regulatory strategy, and the financing decisions that determine whether a program reaches its key value-inflection points.